BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

Stock Information for Marvel Biosciences Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Marvel Biosciences Corp.

BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D
BioVaxys Technology Corp. Closes Debt Settlement Transaction
CSE Bulletin: MOC Eligibility Update
BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M
BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES
BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES
BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS
BioVaxys Licensee SpayVac-for-Wildlife, Inc., Reports Further Positive Single-Dose Efficacy Data for Its Immunocontraceptive Vaccine and Initiation of Regulatory Submission Process

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.